key: cord-0257184-otgli4sk
authors: Peng, Kah-Whye; Carey, Timothy; Lech, Patrycja; Vandergaast, Rianna; Muñoz-Alía, Miguel Á.; Packiriswamy, Nandakumar; Gnanadurai, Clement; Krotova, Karina; Tesfay, Mulu; Ziegler, Christopher; Haselton, Michelle; Sevola, Kara; Lathrum, Chase; Reiter, Samantha; Narjari, Riya; Balakrishnan, Baskar; Suksanpaisan, Lukkana; Sakuma, Toshie; Recker, Jordan; Zhang, Lianwen; Waniger, Scott; Russell, Luke; Petro, Christopher D.; Kyratsous, Christos A.; Baum, Alina; Janecek, Jody L.; Lee, Rachael M.; Ramachandran, Sabarinathan; Graham, Melanie L.; Russell, Stephen J.
title: Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine
date: 2021-10-18
journal: bioRxiv
DOI: 10.1101/2021.10.16.464660
sha: ff46e938ba0dbe704c009b54ec9472adca45834f
doc_id: 257184
cord_uid: otgli4sk

An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.

Full-length human codon-optimized SARS-CoV-2 Spike (S) glycoprotein (NC_045512.2) in 3 7 3 pUC57 was obtained from GenScript (MC_0101081). The plasmid was used as a PCR template to generate a cDNA encoding SARS-CoV-2 spike with a deletion in the nucleotides encoding the VSV-G using the MluI and NheI restriction sites (Fig. 1) . Plasmid was sequence verified and transfected into the BHK-21 cells to facilitate rescue but was not present in subsequent passages 16-24 h before being used for neutralization assays. On the day of assay, increasing dilutions 5 0 8

(1:80, 1:160, 1:320, 1:640, 1:1280, and 1:2560) of serum samples were prepared and mixed with 5 0 9

VSV-SARS2-Fluc in U-bottom suspension cell culture plates to a final volume of 240 µL/well. overlaid onto the Vero-ACE2 monolayers in duplicate. All time points for each animal were 5 1 7 assayed on the same plate. Plates were returned to a 37°C/5% CO 2 incubator for 24-28 hours. D-

luciferin was then added to wells and luminescence was read immediately (30-90 seconds) using 5 1 9

a Tecan M Plex or Tecan Lume instrument (100 ms integration, 100 ms settle time per well).

Virus neutralizing titers were determined for each sample from an individual animal by 5 2 1

calculating the dilution that resulted in luciferase signal greater than 50% of the Day 0 (prior to 5 2 2 treatment) sample for that specific animal (IC 50 ). The dilution was calculated by fitting all 5 2 3

dilutions to a 4-parameter logistic curve fitting model. OptiMEM with 0.0004% trypsin/EDTA was added to each well. Plates were incubated for an 5 4 7

additional 3 days at 37 o C/5% CO 2 before each well was scored for the presence of syncytia, used to evaluate NHP IgA against SARS-CoV-2 spike trimer in a binding ELISA assay. 21. On days 21 (before boost) and 41, blood was collected. Parallel groups of mice were 5 5 7

terminated on day 21 post-immunization for analysis of cellular immune response. CoV-2 spike protein (Cat.# V0589-V08B, Sino Biological) in 50mM carbonate-bicarbonate 5 6 2 buffer, pH 9.6. overnight at 4°C. Plates were washed and blocked with 2% bovine serum serum IgG responses were determined as the dilution that emitted an optimal density exceeding 5 7 3

average of OD values plus three standard deviations of negative serum samples. were counted using automated MabTech IRIS reader with excitation/emission of 490nm/510nm 6 0 7

for IFNγ and 550nm/570nm for IL-4. For murine samples, ELISpot assays were performed using the mouse IFN-gamma ELISpot kit represented as SFC per million cells for S1 and S2 peptide pools combined. Tukey's multiple comparison test or a two-tailed unpaired Student's t test was conducted to 6 2 4

compare differences between vaccine groups and the control group with Bonferroni correction 6 2 5 applied to control the type I error rate for the comparisons. 

Anti-VSV.G mAb cocktail

Anti-spike mAb cocktail

Combined anti-spike and anti-VSV.G Ab 

IM-1 IM-2 PO-1 PO-2 PO-2 PO-1 IM-2 IM-1 IM (n=2) PO (n=2) V a c c i n a t e D 0 V S V - S A R S 2 2 x d a i l y o b s e r v

ProSignal® Dura ECL Reagent (Prometheus #20-301). Protein bands were imaged using a

Neutralizing antibody titers using a live SARS-CoV-2 spike VSV pseudovirus (IMMUNO-6 4 7 COV™) assay [17] . Time points are before (pre) and at 2, 3, and 4 weeks post vaccination. A 6 4 8 log2 scale is used for the y axis.